{"id":41884,"date":"2023-01-23T09:47:35","date_gmt":"2023-01-23T15:47:35","guid":{"rendered":"https:\/\/www.tmc.edu\/?p=41884"},"modified":"2023-05-17T09:22:33","modified_gmt":"2023-05-17T15:22:33","slug":"21-researchers-and-companies-have-been-selected-to-join-the-2023-accelerator-for-cancer-therapeutics","status":"publish","type":"post","link":"https:\/\/www.tmc.edu\/blog\/21-researchers-and-companies-have-been-selected-to-join-the-2023-accelerator-for-cancer-therapeutics\/","title":{"rendered":"21 researchers and companies have been selected to join the 2023 Accelerator for Cancer Therapeutics."},"content":{"rendered":"<p>21 researchers and companies have been selected to join the 2023 Accelerator for Cancer Therapeutics. Launched in 2021, the nine-month program \u2013 funded by the Cancer Prevention and Research Institute of Texas (CPRIT) and partnered with the Gulf Coast Consortia and the University of Texas Medical Branch (UTMB) \u2013 supports investigators and early-stage biotechnology companies spearheading groundbreaking work in the area of cancer therapeutics. Throughout the program, participants will be mentored by a world-class group of scientific, business, and innovation leaders to ultimately be positioned to apply for grants and pitch to investors and corporate partners to further the development of their innovative cancer solutions.<\/p>\n<p>\u201cFor this third cohort, we focused on a strategic and extensive recruitment process, including the evaluation of 1,679 cancer research projects. From 56 applications, we selected 21 participants that will gain access to valuable resources, integrated training and mentorship to prepare for clinical trials,\u201d said Ahmed AlRawi, Program Manager, Accelerator for Cancer Therapeutics. \u201cOur 2023 cohort represents our most diverse cohort to date, including eight companies led by women entrepreneurs. We are excited to continue the momentum and build off the successes of our previous years.\u201d<\/p>\n<p>Since its launch, 45 participants have gone through the accelerator program. Collectively, the entrepreneurs have raised more than $90M in funding (from NIH, CPIRT, and venture capital) and three projects are in the clinic. 2023 cohort participants are focused on a wide range of therapeutic assets, including small molecule (38%), antibody (28%), peptide\/protein (19%), cell therapy (14%) and other (15%). The 2023 cohort kicks off their nine-month program in January.<\/p>\n<p>The participants include:<\/p>\n<ul>\n<li><a href=\"https:\/\/www.researchgate.net\/profile\/Amit-Tripathi-6\">Amit K. Tripathi<\/a> \u2013 UNT-Health Science Center<\/li>\n<li><a href=\"https:\/\/www.linkedin.com\/in\/darshan-gandhi\/\">Darshan Gandhi<\/a> (ImproveBio, LLC)<\/li>\n<li><a href=\"https:\/\/www.uh.edu\/nsm\/biology-biochemistry\/people\/profiles\/frank-mckeon\/\">Frank McKeon<\/a> (Tract Pharmaceutical) \u2013 University of Houston<\/li>\n<li><a href=\"https:\/\/www.linkedin.com\/in\/hemanta-baruah-b662611a\/\">Hemanta Baruah<\/a> (Aakha Biologics)<\/li>\n<li><a href=\"https:\/\/profiles.utsouthwestern.edu\/profile\/202745\/joshua-gruber.html\">Joshua Gruber<\/a> \u2013 UT-Southwestern<\/li>\n<li><a href=\"https:\/\/www.uth.edu\/imm\/faculty\/profile?id=82538dc4-e7dd-4348-989e-10c3107861b3\">Kyoji Tsuchikama<\/a> \u2013 UT Health Science Center-Houston<\/li>\n<li><a href=\"https:\/\/profiles.utsouthwestern.edu\/profile\/94723\/michael-buszczak.html\">Michael Buszczak<\/a> \u2013 UT-Southwestern<\/li>\n<li>Nadezhda (Nadia) German -Texas Tech-Lubbock<\/li>\n<li><a href=\"https:\/\/www.linkedin.com\/in\/parsa-modareszadeh-6203b9209\/\">Parsa Modareszadeh<\/a> (HemePro Therapeutics) \u2013 UT-Dallas<\/li>\n<li><a href=\"https:\/\/www.linkedin.com\/in\/robert-kruse\/\">Robert Kruse<\/a> (HydroGene Therapeutics)<\/li>\n<li><a href=\"https:\/\/www.bcm.edu\/people-search\/xiang-zhang-33649\">Xiang Zhang<\/a> \u2013 Baylor College of Medicine<\/li>\n<li><a href=\"https:\/\/biomedical.engineering.unt.edu\/people\/youngwook-won\">Youngwook Won<\/a> (Singular Immune, Inc.)<\/li>\n<li><a href=\"https:\/\/profiles.utsouthwestern.edu\/profile\/14386\/zhi-ping-liu.html\">Zhi-Ping Liu<\/a> (Raphael Pharmaceutical LLC) \u2013 UT-Southwestern<\/li>\n<li><a href=\"https:\/\/www.linkedin.com\/in\/jonathan-arambula-8719642b\/\">Jonathan Arambula<\/a> (InnovoTEX Inc.)<\/li>\n<li><a href=\"https:\/\/utswmed.org\/doctors\/isaac-chan\/\">Isaac Chan<\/a> \u2013 UT-Southwestern<\/li>\n<li>Ruptakine Inc. \u2013 UT Health Science Center-Houston<\/li>\n<li><a href=\"https:\/\/scholars.library.tamu.edu\/vivo\/display\/n5b9879a8\/Persons\/View%20All\">Jim Song<\/a> (Tranquility Biodesign) \u2013 Texas A&amp;M-College Station<\/li>\n<li><a href=\"https:\/\/graduate.rice.edu\/student-ambassadors\/rosa-selenia-guerra-resendez\">Rosa Selenia Guerra-Resendez (<\/a>Quetzal Bio, LLC) \u2013 Rice University<\/li>\n<li><a href=\"https:\/\/faculty.mdanderson.org\/profiles\/cassian_yee.html\">Cassian Yee<\/a> (Mongoose Bio, LLC) \u2013 UT-MD Anderson Cancer Center<\/li>\n<li><a href=\"https:\/\/directory.uthscsa.edu\/academics\/profile\/raom\">Manjeet Rao<\/a> (Niragen, Inc.) \u2013 UT Health Science Center-San Antonio<\/li>\n<li><a href=\"https:\/\/www.linkedin.com\/in\/gvela1\/\">Guillermo Vela<\/a> (NeuScience)<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>21 researchers and companies have been selected to join the 2023 Accelerator for Cancer Therapeutics. Launched in 2021, the nine-month program \u2013 funded by the Cancer Prevention and Research Institute of Texas (CPRIT) and partnered with the Gulf Coast Consortia and the University of Texas Medical Branch (UTMB) \u2013 supports investigators and early-stage biotechnology companies [&hellip;]<\/p>\n","protected":false},"author":41,"featured_media":41886,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[1],"tags":[43],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>21 researchers and companies have been selected to join the 2023 Accelerator for Cancer Therapeutics. - Texas Medical Center<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.tmc.edu\/blog\/21-researchers-and-companies-have-been-selected-to-join-the-2023-accelerator-for-cancer-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"21 researchers and companies have been selected to join the 2023 Accelerator for Cancer Therapeutics. - Texas Medical Center\" \/>\n<meta property=\"og:description\" content=\"21 researchers and companies have been selected to join the 2023 Accelerator for Cancer Therapeutics. Launched in 2021, the nine-month program \u2013 funded by the Cancer Prevention and Research Institute of Texas (CPRIT) and partnered with the Gulf Coast Consortia and the University of Texas Medical Branch (UTMB) \u2013 supports investigators and early-stage biotechnology companies [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.tmc.edu\/blog\/21-researchers-and-companies-have-been-selected-to-join-the-2023-accelerator-for-cancer-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Texas Medical Center\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-23T15:47:35+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-05-17T15:22:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.tmc.edu\/wp-content\/uploads\/2023\/01\/IMG_5809-2-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1707\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Ida Sameri Beik\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Ida Sameri Beik\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.tmc.edu\/blog\/21-researchers-and-companies-have-been-selected-to-join-the-2023-accelerator-for-cancer-therapeutics\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.tmc.edu\/blog\/21-researchers-and-companies-have-been-selected-to-join-the-2023-accelerator-for-cancer-therapeutics\/\"},\"author\":{\"name\":\"Ida Sameri Beik\",\"@id\":\"https:\/\/www.tmc.edu\/#\/schema\/person\/07a9a76a46e1a30c50f1a0b8117b2cbe\"},\"headline\":\"21 researchers and companies have been selected to join the 2023 Accelerator for Cancer Therapeutics.\",\"datePublished\":\"2023-01-23T15:47:35+00:00\",\"dateModified\":\"2023-05-17T15:22:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.tmc.edu\/blog\/21-researchers-and-companies-have-been-selected-to-join-the-2023-accelerator-for-cancer-therapeutics\/\"},\"wordCount\":376,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.tmc.edu\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.tmc.edu\/blog\/21-researchers-and-companies-have-been-selected-to-join-the-2023-accelerator-for-cancer-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.tmc.edu\/wp-content\/uploads\/2023\/01\/IMG_5809-2-scaled.jpg\",\"keywords\":[\"Innovation\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.tmc.edu\/blog\/21-researchers-and-companies-have-been-selected-to-join-the-2023-accelerator-for-cancer-therapeutics\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.tmc.edu\/blog\/21-researchers-and-companies-have-been-selected-to-join-the-2023-accelerator-for-cancer-therapeutics\/\",\"url\":\"https:\/\/www.tmc.edu\/blog\/21-researchers-and-companies-have-been-selected-to-join-the-2023-accelerator-for-cancer-therapeutics\/\",\"name\":\"21 researchers and companies have been selected to join the 2023 Accelerator for Cancer Therapeutics. - Texas Medical Center\",\"isPartOf\":{\"@id\":\"https:\/\/www.tmc.edu\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.tmc.edu\/blog\/21-researchers-and-companies-have-been-selected-to-join-the-2023-accelerator-for-cancer-therapeutics\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.tmc.edu\/blog\/21-researchers-and-companies-have-been-selected-to-join-the-2023-accelerator-for-cancer-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.tmc.edu\/wp-content\/uploads\/2023\/01\/IMG_5809-2-scaled.jpg\",\"datePublished\":\"2023-01-23T15:47:35+00:00\",\"dateModified\":\"2023-05-17T15:22:33+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.tmc.edu\/blog\/21-researchers-and-companies-have-been-selected-to-join-the-2023-accelerator-for-cancer-therapeutics\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.tmc.edu\/blog\/21-researchers-and-companies-have-been-selected-to-join-the-2023-accelerator-for-cancer-therapeutics\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.tmc.edu\/blog\/21-researchers-and-companies-have-been-selected-to-join-the-2023-accelerator-for-cancer-therapeutics\/#primaryimage\",\"url\":\"https:\/\/www.tmc.edu\/wp-content\/uploads\/2023\/01\/IMG_5809-2-scaled.jpg\",\"contentUrl\":\"https:\/\/www.tmc.edu\/wp-content\/uploads\/2023\/01\/IMG_5809-2-scaled.jpg\",\"width\":2560,\"height\":1707},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.tmc.edu\/blog\/21-researchers-and-companies-have-been-selected-to-join-the-2023-accelerator-for-cancer-therapeutics\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.tmc.edu\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"21 researchers and companies have been selected to join the 2023 Accelerator for Cancer Therapeutics.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.tmc.edu\/#website\",\"url\":\"https:\/\/www.tmc.edu\/\",\"name\":\"Texas Medical Center\",\"description\":\"Leader in Collaborative Medicine and Research\",\"publisher\":{\"@id\":\"https:\/\/www.tmc.edu\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.tmc.edu\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.tmc.edu\/#organization\",\"name\":\"Texas Medical Center\",\"url\":\"https:\/\/www.tmc.edu\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.tmc.edu\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.tmc.edu\/wp-content\/uploads\/2016\/02\/logo.png\",\"contentUrl\":\"https:\/\/www.tmc.edu\/wp-content\/uploads\/2016\/02\/logo.png\",\"width\":228,\"height\":72,\"caption\":\"Texas Medical Center\"},\"image\":{\"@id\":\"https:\/\/www.tmc.edu\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.tmc.edu\/#\/schema\/person\/07a9a76a46e1a30c50f1a0b8117b2cbe\",\"name\":\"Ida Sameri Beik\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.tmc.edu\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/037b0079c3a8640250c12cd854ea5453?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/037b0079c3a8640250c12cd854ea5453?s=96&d=mm&r=g\",\"caption\":\"Ida Sameri Beik\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"21 researchers and companies have been selected to join the 2023 Accelerator for Cancer Therapeutics. - Texas Medical Center","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.tmc.edu\/blog\/21-researchers-and-companies-have-been-selected-to-join-the-2023-accelerator-for-cancer-therapeutics\/","og_locale":"en_US","og_type":"article","og_title":"21 researchers and companies have been selected to join the 2023 Accelerator for Cancer Therapeutics. - Texas Medical Center","og_description":"21 researchers and companies have been selected to join the 2023 Accelerator for Cancer Therapeutics. Launched in 2021, the nine-month program \u2013 funded by the Cancer Prevention and Research Institute of Texas (CPRIT) and partnered with the Gulf Coast Consortia and the University of Texas Medical Branch (UTMB) \u2013 supports investigators and early-stage biotechnology companies [&hellip;]","og_url":"https:\/\/www.tmc.edu\/blog\/21-researchers-and-companies-have-been-selected-to-join-the-2023-accelerator-for-cancer-therapeutics\/","og_site_name":"Texas Medical Center","article_published_time":"2023-01-23T15:47:35+00:00","article_modified_time":"2023-05-17T15:22:33+00:00","og_image":[{"width":2560,"height":1707,"url":"https:\/\/www.tmc.edu\/wp-content\/uploads\/2023\/01\/IMG_5809-2-scaled.jpg","type":"image\/jpeg"}],"author":"Ida Sameri Beik","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Ida Sameri Beik","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.tmc.edu\/blog\/21-researchers-and-companies-have-been-selected-to-join-the-2023-accelerator-for-cancer-therapeutics\/#article","isPartOf":{"@id":"https:\/\/www.tmc.edu\/blog\/21-researchers-and-companies-have-been-selected-to-join-the-2023-accelerator-for-cancer-therapeutics\/"},"author":{"name":"Ida Sameri Beik","@id":"https:\/\/www.tmc.edu\/#\/schema\/person\/07a9a76a46e1a30c50f1a0b8117b2cbe"},"headline":"21 researchers and companies have been selected to join the 2023 Accelerator for Cancer Therapeutics.","datePublished":"2023-01-23T15:47:35+00:00","dateModified":"2023-05-17T15:22:33+00:00","mainEntityOfPage":{"@id":"https:\/\/www.tmc.edu\/blog\/21-researchers-and-companies-have-been-selected-to-join-the-2023-accelerator-for-cancer-therapeutics\/"},"wordCount":376,"commentCount":0,"publisher":{"@id":"https:\/\/www.tmc.edu\/#organization"},"image":{"@id":"https:\/\/www.tmc.edu\/blog\/21-researchers-and-companies-have-been-selected-to-join-the-2023-accelerator-for-cancer-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.tmc.edu\/wp-content\/uploads\/2023\/01\/IMG_5809-2-scaled.jpg","keywords":["Innovation"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.tmc.edu\/blog\/21-researchers-and-companies-have-been-selected-to-join-the-2023-accelerator-for-cancer-therapeutics\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.tmc.edu\/blog\/21-researchers-and-companies-have-been-selected-to-join-the-2023-accelerator-for-cancer-therapeutics\/","url":"https:\/\/www.tmc.edu\/blog\/21-researchers-and-companies-have-been-selected-to-join-the-2023-accelerator-for-cancer-therapeutics\/","name":"21 researchers and companies have been selected to join the 2023 Accelerator for Cancer Therapeutics. - Texas Medical Center","isPartOf":{"@id":"https:\/\/www.tmc.edu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.tmc.edu\/blog\/21-researchers-and-companies-have-been-selected-to-join-the-2023-accelerator-for-cancer-therapeutics\/#primaryimage"},"image":{"@id":"https:\/\/www.tmc.edu\/blog\/21-researchers-and-companies-have-been-selected-to-join-the-2023-accelerator-for-cancer-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.tmc.edu\/wp-content\/uploads\/2023\/01\/IMG_5809-2-scaled.jpg","datePublished":"2023-01-23T15:47:35+00:00","dateModified":"2023-05-17T15:22:33+00:00","breadcrumb":{"@id":"https:\/\/www.tmc.edu\/blog\/21-researchers-and-companies-have-been-selected-to-join-the-2023-accelerator-for-cancer-therapeutics\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.tmc.edu\/blog\/21-researchers-and-companies-have-been-selected-to-join-the-2023-accelerator-for-cancer-therapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.tmc.edu\/blog\/21-researchers-and-companies-have-been-selected-to-join-the-2023-accelerator-for-cancer-therapeutics\/#primaryimage","url":"https:\/\/www.tmc.edu\/wp-content\/uploads\/2023\/01\/IMG_5809-2-scaled.jpg","contentUrl":"https:\/\/www.tmc.edu\/wp-content\/uploads\/2023\/01\/IMG_5809-2-scaled.jpg","width":2560,"height":1707},{"@type":"BreadcrumbList","@id":"https:\/\/www.tmc.edu\/blog\/21-researchers-and-companies-have-been-selected-to-join-the-2023-accelerator-for-cancer-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.tmc.edu\/"},{"@type":"ListItem","position":2,"name":"21 researchers and companies have been selected to join the 2023 Accelerator for Cancer Therapeutics."}]},{"@type":"WebSite","@id":"https:\/\/www.tmc.edu\/#website","url":"https:\/\/www.tmc.edu\/","name":"Texas Medical Center","description":"Leader in Collaborative Medicine and Research","publisher":{"@id":"https:\/\/www.tmc.edu\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.tmc.edu\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.tmc.edu\/#organization","name":"Texas Medical Center","url":"https:\/\/www.tmc.edu\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.tmc.edu\/#\/schema\/logo\/image\/","url":"https:\/\/www.tmc.edu\/wp-content\/uploads\/2016\/02\/logo.png","contentUrl":"https:\/\/www.tmc.edu\/wp-content\/uploads\/2016\/02\/logo.png","width":228,"height":72,"caption":"Texas Medical Center"},"image":{"@id":"https:\/\/www.tmc.edu\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.tmc.edu\/#\/schema\/person\/07a9a76a46e1a30c50f1a0b8117b2cbe","name":"Ida Sameri Beik","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.tmc.edu\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/037b0079c3a8640250c12cd854ea5453?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/037b0079c3a8640250c12cd854ea5453?s=96&d=mm&r=g","caption":"Ida Sameri Beik"}}]}},"acf":{"author":""},"_links":{"self":[{"href":"https:\/\/www.tmc.edu\/wp-json\/wp\/v2\/posts\/41884"}],"collection":[{"href":"https:\/\/www.tmc.edu\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.tmc.edu\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.tmc.edu\/wp-json\/wp\/v2\/users\/41"}],"replies":[{"embeddable":true,"href":"https:\/\/www.tmc.edu\/wp-json\/wp\/v2\/comments?post=41884"}],"version-history":[{"count":3,"href":"https:\/\/www.tmc.edu\/wp-json\/wp\/v2\/posts\/41884\/revisions"}],"predecessor-version":[{"id":43204,"href":"https:\/\/www.tmc.edu\/wp-json\/wp\/v2\/posts\/41884\/revisions\/43204"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.tmc.edu\/wp-json\/wp\/v2\/media\/41886"}],"wp:attachment":[{"href":"https:\/\/www.tmc.edu\/wp-json\/wp\/v2\/media?parent=41884"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.tmc.edu\/wp-json\/wp\/v2\/categories?post=41884"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.tmc.edu\/wp-json\/wp\/v2\/tags?post=41884"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}